Vildagliptin and biguanide on postprandial blood glucose and vascular endothelial function in type 2 diabetic patients with coronary artery disease

Vildagliptin and biguanide on postprandial blood glucose and vascular endothelial function in type 2 diabetic patients with coronary artery disease - VIBRATE-J study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010624

Enrollment

Registered

2013-05-01

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients with coronary artery disease

Interventions

Vildagliptin Metformin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with HbA1 >= 6.9% (NGSP) even after dietary and exercise therapies 2) Patients with CAD 3) Patients who give informed consent 4) Patients aged 20 years or older

Exclusion criteria

Exclusion criteria: 1) Patients who has a history of adverse events with vildagliptin or biganide 2) Patients treated with antidiabetes agents 3) Ongoing treatment with insulin 4) Patients with diabetic ketoacidosis or diabetic coma or type 1 diabetes 5) Patients with severe liver dysfunction 6) Patients with moderate or severe renal disorders (creatinine level >= 1.5 mg/dL [men] or >= 1.3 mg/dL [women]) 7) Pregnant or nursing women 8) Patients with severe illness 9) Patients who judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
Changes of blood glucose, insulin, and lipids	—

Secondary

Measure	Time frame
Changes of vascular endothelial function	—

Countries

Japan

Contacts

Public ContactKazunori Shimada

Juntendo University School of Medicine Department of Cardiology

shimakaz@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026